Bridge Biotherapeutics (KQ288330), a South Korea-based clinical-stage biotech company, announced on Tuesday that it has entered a research collaboration with Dr. Raul Torres's Lab at the University of Colorado School of Medicine.
The partnership is to concentrate on exploring the potential of BBT-877, a novel autotaxin (ATX) inhibitor, as an immuno-oncology treatment for cancer.
Throughout his earlier and ongoing research, Dr Raul Torres, professor of Immunology and Microbiology at the University of Colorado School of Medicine, has shown that lysophosphatidic acid (LPA) plays a role in modulating CD8 T cell immunosurveillance and metabolism, ultimately disrupting the body's anti-tumour immunity.
According to the terms of the collaboration, Bridge Biotherapeutics is to provide financial support and access to BBT-877, while Dr Raul Torres's Lab is to contribute its expertise in immunology and cancer biology. Both parties will together conduct preclinical studies to assess the therapeutic potential of BBT-877 in improving anti-tumour immunity.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration